In conclusion, our study showed an increased response rate and improved survival of cetuximab-containing salvage therapy in patients with R/M HNSCC after progression on PD-1 immunotherapy in the first-line treatment. Here, PDCD1 is linked to head and neck squamous cell carcinoma.